Lyophilization Services for Biopharmaceuticals Market: Rapid Growth in Contract Manufacturing

Lyophilization involves freeze drying of products. In pharmaceutical industries this process is widely used to increase the self-life of antibiotics, vaccines, and protein based drugs. Biopharmaceutical companies are using lyophilization services to keep APIs and drugs sterile. Focus towards enhanced manufacturing practices is increasing the demand for lyophilization services. The growing importance of lyophilization services in biopharmaceuticals market is attributed to the factors such as rising demand for lyophilized products and rapid growth in contract manufacturing and lyophilization services across the world. However, the market is likely to get impacted by the demerits associated with lyophilization process such as leakage during filling, during the forecast period.

Get Sample PDF Copy of Lyophilization Services for Biopharmaceuticals Market at: https://www.theinsightpartners.com/sample/TIPRE00009286/?utm_source=OpenPR&utm_medium=10144

The lyophilization services for biopharmaceuticals market was valued at US$ 702.06 million in 2019 and is projected to reach US$ 1,456.74 million by 2027; it is expected to grow at a CAGR of 9.7% from 2020 to 2027.

ATTWILL Medical Solutions; Axcellerate Pharma LLC.; AB BioTechnologies, Inc.; Berkshire Sterile Manufacturing, Inc.; Emergent BioSolutions; LSNE Contract Manufacturing; Albany Molecular Research (AMRI); Lyophilization Technology, Inc.; Jubilant HollisterStier LLC; Biofortuna Ltd; and Synerlab Group are some of the prominent players operating in the lyophilization services for biopharmaceuticals market.

The market players are focused on organic strategies to sustain their position in the market. For instance, in June 2020, Berkshire Sterile Manufacturing (BSM) has secured US$ 16.5 million financing from Berkshire Bank and Lee Bank to expand its operations in Lee. This financing will be used to add manufacturing capabilities including an additional state-of-the-art robotic line for producing sterile drug products such as vials, syringes, and cartridges.

Based on service type, the lyophilization service for biopharmaceuticals market is segmented into product and cycle development, clinical manufacturing, commercial manufacturing, and freeze drying analytical services. In terms of service type, the commercial manufacturing segment held the highest share of the lyophilization services for biopharmaceuticals market in 2019; however, the product and cycle development segment is anticipated to witness a significant growth rate during the forecast period. The growth of the market is attributed to the advantages offered by the lyophilization process such as increased shelf life for both small and large molecule drugs, stabilizing formulation by commercially validated method, and reduces cost for complex logistics such as rigorous cold-chain custody validation regimes and constant documentable refrigeration at the dispensary level.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.

Download the Latest COVID-19 Analysis on Lyophilization Services for Biopharmaceuticals Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00009286?utm_source=OpenPR&utm_medium=10144

The market for biopharmaceuticals continues to expand worldwide, and they have been the primary growth driver for the pharmaceutical industry. Biopharmaceuticals will continue to provide a significant growth for the pharmaceutical market during the next five years. Biopharmaceutical parenteral manufacturing has expanded in recent years as more therapeutic biologics have been approved for the market. Biotechnology companies continue to outsource to contract manufacturing organizations (CMOs) as a way to meet their fill-and-finish needs and reduce risk.

For drug developers to set up in-house lyophilization capabilities and operations, specialized equipment and expertise are required, which is an expensive and time-consuming process. To decrease the overall cost of the product and yield cost savings, biopharmaceutical companies continue to outsource such operations to contract manufacturing organizations (CMOs). Outsourcing is cheaper and increases the efficiency of manufacturing processes. Additionally, it allows biotechnology companies to redirect resources to other areas.

Order a Copy of Lyophilization Services for Biopharmaceuticals Market Shares, Strategies and Forecasts 2021-2027 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00009286/?utm_source=OpenPR&utm_medium=10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

This release was published on openPR.